Errol B. De Souza, Ph.D.
President and Chief Executive Officer
Dr. De Souza is currently president and Chief Executive Officer of Neuropore Therapies a biopharmaceutical company developing disease modifying treatment for Parkinson’s Disease, Alzheimer’s Disease and other neurodegenerative disorders by targeting molecular mechanisms of autophagy and neuro-inflammation to facilitate clearance of misfolded proteins. He has substantial experience as an executive in the biopharmaceutical industry, having founded companies (Neurocrine Biosciences, Nasdaq: NBIX) and served as President and Chief Executive Officer of several public (Biodel, Nasdaq: BIOD; Synaptic Pharmaceutical Corp., Nasdaq: SNAP) and private (Archemix) biotech companies.
Dr. De Souza has raised hundreds of million dollars in capital in private (venture) and public sectors. Also, he has been involved in taking companies public (Neurocrine Biosciences IPO), executed M&A deals including Synaptic Pharmaceuticals sale to H. Lundbeck A/S, and has served in a number of high-ranking R&D roles, including Senior Vice President and U.S. head of R&D for Aventis (now Sanofi; 1998-2002), co-founder and Executive Vice President of Research and Development at Neurocrine Biosciences (1992-1998), and Head of CNS Diseases Research at DuPont Merck (1990 – 1992). He has extensive Board experience and serves or has served on the Board of Directors of several private companies and public companies.
Dr. De Souza received his B.A in physiology and his Ph.D. in neuroendocrinology from the University of Toronto and he received his postdoctoral fellowship in neuroscience from The Johns Hopkins University School of Medicine.
Douglas Bonhaus, Ph.D.
Chief Operating Officer
Dr. Bonhaus is a well-established and recognized leader in the pharmaceutical industry with more than twenty five years of experience building and leading drug discovery organizations dedicated to the discovery and development of new therapeutics for neurological and psychiatric disorders. Dr. Bonhaus has served as the Chief Operating Officer of Neuropore Therapies, Inc. since 2011.
His academic training and experience include receiving his Ph.D. in pharmacology and toxicology from the University of Arizona and completing postdoctoral training in the Department of Medicine at Duke University. He was subsequently appointed to a research assistant professor position in the Division of Neurology at Duke University. Dr. Bonhaus also taught pharmacology and drug discovery through an extension service at the University of California Berkeley.
Before joining Neuropore Therapies, Dr. Bonhaus has held industry positions at Syntex, Roche and ACADIA pharmaceuticals; where he served as the Vice President of Biosciences. Dr. Bonhaus was also co-founder and Chief Scientific Officer for Denysias Bioscience, a start-up company focused on developing a novel therapeutic for a psychiatric indication in Parkinson's disease. Key scientific and leadership contributions in these positions have resulted in number of novel therapeutic agents being advanced to market or clinical development.
Doug Bonhaus has been awarded a number of NIH and private foundation research grants. He is an inventor on several patents and is a principal author on over a hundred peer-reviewed publications.
Paul Gotfredson, CPA
Chief Financial Officer
Mr. Gotfredson has over 25 years of experience working with companies in the life science industry and has served as Chief Financial Officer for Neuropore Therapies, Inc. since 2009. Mr. Gotfredson manages a financial consulting practice providing CFO services for life science and hi-tech companies since 2004. Prior to that he held the positions of Director of Finance with Genicon Sciences, Inc., Controller with Molecular Biosystems, Inc., and Assistant Controller with Casio Manufacturing Corporation.
Mr. Gotfredson began his career working in the San Diego offices of Ernst and Young. He received his BS in Accounting from the University of San Diego in 1989 and was licensed as a CPA in the state of California in 1992.
Wolf Wrasidlo, Ph.D.
Executive Director, Medicinal Chemistry
Dr. Wrasidlo is one of the founding members of Neuropore Therapies Inc. and a research chemist with an extremely distinguished 40 plus year career in academia and the pharmaceutical industry.
Dr. Wrasidlo received a B.S. in Chemistry from San Diego State University and a Ph.D. in Organic Chemistry from the University of Erlangen and San Diego State University.
He has held several senior level positions in academia including Director of the Chemical Biology Program at the UCSD Moores Cancer Center, UCSD School of Medicine, The Scripps Research Institute, Humboldt University Berlin Medical School, University of Tuebingen Childrens’ Hospital, and Columbia University. He has held positions in industry as a Distinguished Research Fellow at TargeGen, Inc., a Founder and the Head of Research at Brunswick Biotechnetics, a Research Scientist at General Atomics, and a member of the Member- Macromolecular Chemistry Group at the Boeing Scientific Research Institute.
Dr. Wrasidlo is a member of the American Chemical Society, the New York Academy of Science, the American Association for the Advancement of Science, the American Association for Cancer Research, and the American Society of Haematology as well as a member of the editorial board of the Journal of Pharmaceutics. He received the Kirkpatric American Chemical Society Award in Chemical Engineering, and the UCSD Connect award for the most innovative product in biotechnology R&D. He has authored over 200 scientific publications and the inventor on over 80 patents or patent applications.
Diana L. Price, Ph.D.
Senior Director, Neurosciences and In Vivo Pharmacology
Dr. Price is the Senior Director of Neurosciences at Neuropore Therapies where she has lead research efforts supporting drug discovery, preclinical development, and translational biomarker studies since 2011.
Dr. Price received her doctorate in Neurosciences from the UCSD School of Medicine in 2000. She conducted a postdoctoral appointment from 2000-2003, and then transitioned to an academic research faculty member at the National Center for Microscopy and Imaging Research at UCSD while conducting collaborative multi-scale imaging, behavioral pharmacology and bioinformatics research in pursuit of characterizing translational models of CNS disorders.
Dr. Price moved to industry in 2007, with a position at ACADIA Pharmaceuticals as a member of the drug-discovery team for neurological and psychiatric disorders utilizing behavioral pharmacology and neuroanatomical techniques to evaluate drug candidates and provide proof of concept data for preclinical development of Pimavanserin (Nuplazid™) for Parkinson’s and Alzheimer’s disease psychosis.
Martin B. Gill, Ph.D.
Director, In Vitro Pharmacology
Dr. Gill received his doctorate in Neuroscience and Cell Biology from the University of Texas-Medical Branch in 2007 where his research focused on apoptotic/necroptotic signaling in neurodegeneration models. He conducted post-doctoral work from 2007-2009 at Northwestern University, Feinberg School of Medicine, investigating glutamate receptor biogenesis and electrophysiology, in addition to supporting medicinal chemistry efforts by evaluating novel marine-based pharmacophores for their utility in correcting abnormal neuronal function.
Dr. Gill transitioned to industry in 2009 as a research scientist with Eli Lilly where he served as a member of the Neuroscience Discovery department supporting target identification/validation and lead optimization efforts. In 2011, Dr. Gill accepted a Research Investigator position in the Neuroscience Discovery department at Bristol-Myers Squibb (BMS) where he managed a lab of senior and junior research scientists focused on in vitro/in vivo assay development to support portfolio program progression. Promoted in 2013 to Senior Research Investigator in BMS’ department of Genetically-Defined Disease and Genomics, Dr. Gill served as biology co-chair for internal small molecule and antisense programs as well as led biology efforts in evaluating in-licensing opportunities. In addition, Dr. Gill collaborated with the research informatics, technology and automation team to fully automate primary neuronal culture and downstream cell biology assay endpoints including their analysis.
Dr. Gill joined the Neuropore Therapies, Inc. team in January 2016.